Suppr超能文献

肥胖症的体重管理——过去与现在

Weight management in obesity - past and present.

作者信息

Haslam D

机构信息

The Cheyne Society, Datchworth, UK.

出版信息

Int J Clin Pract. 2016 Mar;70(3):206-17. doi: 10.1111/ijcp.12771. Epub 2016 Jan 26.

Abstract

AIMS

To describe the treatment of obesity from ancient times to present day.

METHODS

Articles reporting the development of anti-obesity therapies were identified through a search for 'anti-obesity' AND 'pharmacotherapy' AND 'development' within the title or abstract on PubMed and 'obesity' in ClinicalTrials.gov. Relevant articles and related literature were selected for inclusion.

RESULTS

Stone-age miniature obese female statuettes indicate the existence and cultural significance of obesity as long as 30,000 years ago. Records from Ancient Egyptian and Biblical eras through Greco-Roman to Medieval times indicate that obesity was present throughout the major periods of history, although peoples of previous centuries would probably have experienced overweight and obesity as exceptional rather than normal. Health risks of obesity were noted by the Greek physician Hippocrates (460-377 BCE) when the earliest anti-obesity recommendations on diet, exercise, lifestyle and use of emetics and cathartics were born. These recommendations remained largely unchanged until the early 20th century, when spreading urbanisation, increasingly sedentary jobs and greater availability of processed foods produced a sharp rise in obesity. This led to the need for new, more effective, ways to lose weight, to address comorbidities associated with obesity, and to attain the current cultural ideal of slimness. Drug companies of the 1940s and 1950s produced a series of anti-obesity pharmacotherapies in short succession, based largely on amphetamines. Increased regulation of drug development in the 1960s and new efficacy requirements for weight-loss drugs led to rapid reduction in anti-obesity therapies available by the early 1990s.

CONCLUSION

In the last two decades, several new and emerging therapies have been approved or are in development to provide safe, long-term pharmacological agents for the treatment of obesity.

摘要

目的

描述从古至今肥胖症的治疗情况。

方法

通过在PubMed的标题或摘要中搜索“抗肥胖”“药物治疗”和“发展”,以及在ClinicalTrials.gov中搜索“肥胖症”,识别报告抗肥胖疗法发展的文章。选择相关文章及相关文献纳入研究。

结果

石器时代的微型肥胖女性小雕像表明,肥胖症在3万年前就已存在并具有文化意义。从古埃及和圣经时代到希腊罗马时代再到中世纪的记录表明,肥胖症在历史的主要时期都存在,尽管前几个世纪的人们可能将超重和肥胖视为例外而非正常现象。希腊医生希波克拉底(公元前460 - 377年)指出了肥胖症的健康风险,同时诞生了最早关于饮食、运动、生活方式以及使用催吐剂和泻药的抗肥胖建议。这些建议在很大程度上一直未变,直到20世纪初,城市化的蔓延、越来越多的久坐工作以及加工食品的更多供应导致肥胖症急剧增加。这就需要新的、更有效的减肥方法,以解决与肥胖症相关的合并症,并实现当前文化所推崇的苗条理想。20世纪40年代和50年代的制药公司接连推出了一系列主要基于安非他明的抗肥胖药物疗法。20世纪60年代对药物研发的监管加强以及对减肥药物新的疗效要求,导致到20世纪90年代初可用的抗肥胖疗法迅速减少。

结论

在过去二十年中,几种新出现的疗法已获批准或正在研发中,以提供用于治疗肥胖症的安全、长期的药物制剂。

相似文献

1
Weight management in obesity - past and present.
Int J Clin Pract. 2016 Mar;70(3):206-17. doi: 10.1111/ijcp.12771. Epub 2016 Jan 26.
2
[A trip through the history of obesity].
Praxis (Bern 1994). 2013 Jan 16;102(2):77-83. doi: 10.1024/1661-8157/a001169.
4
Obesity, body image and diet drugs: 100 years of change.
Mol Interv. 2008 Apr;8(2):64-9. doi: 10.1124/mi.8.2.2.
5
Chapter 33: the history of movement disorders.
Handb Clin Neurol. 2010;95:501-46. doi: 10.1016/S0072-9752(08)02133-7.
7
History of human parasitic diseases.
Infect Dis Clin North Am. 2004 Jun;18(2):171-88, table of contents. doi: 10.1016/j.idc.2004.01.001.
8
History of cardiac anatomy: a comprehensive review from the Egyptians to today.
Clin Anat. 2016 Apr;29(3):270-84. doi: 10.1002/ca.22705. Epub 2016 Mar 11.
9
Esophageal cancer: a historical perspective.
Gastroenterol Clin North Am. 2009 Mar;38(1):1-15, vii. doi: 10.1016/j.gtc.2009.01.003.

引用本文的文献

1
The Impact of New Weight-Loss Medications on Bariatric Surgery and Surgeon Employment.
Cureus. 2025 May 11;17(5):e83903. doi: 10.7759/cureus.83903. eCollection 2025 May.
3
[The history of the pharmacotherapy of obesity].
Probl Endokrinol (Mosk). 2025 May 20;71(2):82-92. doi: 10.14341/probl13469.
4
SHORT HISTORY OF OBESITY.
Acta Endocrinol (Buchar). 2024 Apr-Jun;20(2):207-211. doi: 10.4183/aeb.2024.207. Epub 2025 Jan 18.
6
Obesity from a sign of being rich to a disease of the new age: A historical review.
Health Sci Rep. 2023 Nov 1;6(11):e1670. doi: 10.1002/hsr2.1670. eCollection 2023 Nov.
7
Notifications and Health Consequences of Unauthorized Pharmaceuticals in Food Supplements.
Pharmacy (Basel). 2023 Sep 23;11(5):154. doi: 10.3390/pharmacy11050154.

本文引用的文献

1
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
N Engl J Med. 2015 Jul 2;373(1):11-22. doi: 10.1056/NEJMoa1411892.
2
Cognitive and autonomic determinants of energy homeostasis in obesity.
Nat Rev Endocrinol. 2015 Aug;11(8):489-501. doi: 10.1038/nrendo.2015.103. Epub 2015 Jun 30.
3
Comorbidity associated with obesity in a large population: The APNA study.
Obes Res Clin Pract. 2015 Sep-Oct;9(5):435-47. doi: 10.1016/j.orcp.2015.04.003. Epub 2015 May 13.
4
Efficacy and safety of beloranib for weight loss in obese adults: a randomized controlled trial.
Diabetes Obes Metab. 2015 Jun;17(6):566-572. doi: 10.1111/dom.12457. Epub 2015 Mar 31.
5
Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults.
Obesity (Silver Spring). 2013 Nov;21(11):2163-71. doi: 10.1002/oby.20584. Epub 2013 Oct 17.
6
Therapeutic potential of cannabinoid medicines.
Drug Test Anal. 2014 Jan-Feb;6(1-2):24-30. doi: 10.1002/dta.1529. Epub 2013 Sep 4.
8
Addiction potential of phentermine prescribed during long-term treatment of obesity.
Int J Obes (Lond). 2014 Feb;38(2):292-8. doi: 10.1038/ijo.2013.74. Epub 2013 May 17.
9
Phentermine, sibutramine and affective disorders.
Clin Psychopharmacol Neurosci. 2013 Apr;11(1):7-12. doi: 10.9758/cpn.2013.11.1.7. Epub 2013 Apr 24.
10
Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials.
Circ Cardiovasc Imaging. 2013 Jul;6(4):560-7. doi: 10.1161/CIRCIMAGING.112.000128. Epub 2013 May 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验